Pakistan Science Abstracts
Article details & metrics
No Detail Found!!
Urticaria in COVID-19 Patient Treated with Lopinavir/ Ritonavir
Author(s):
1. C.R.S. Prakoeswa: Department of Dermatology & Venereology, Airlangga University/ Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
2. Damayanti: Department of Dermatology & Venereology, Airlangga University/ Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
3. S. Anggraeni: Department of Dermatology & Venereology, Airlangga University/ Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
4. M.A. Umborowati: Department of Dermatology & Venereology, Airlangga University/ Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
5. M.D. Alinda: Department of Dermatology & Venereology, Airlangga University/ Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
6. N. Tanojo: Department of Dermatology & Venereology, Airlangga University/ Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
7. J.M.R. Tamba: Department of Dermatology & Venereology, Airlangga University/ Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
8. B. Yogatri: Department of Dermatology & Venereology, Airlangga University/ Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
9. Soedarsono: Department of Pulmonology, Airlangga University/ Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
10. A. Permatasari: Department of Pulmonology, Airlangga University/ Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
11. B.P. Semedi: Departement of Anesthesiology & Reanimation, Airlangga University/ Dr. Soetomo General Academic Hospital, Surabaya-Indonesia.
Abstract:
The unknown pneumonia was first found in Wuhan, China in December 2019. A novel corona virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was isolated from lower respiratory tract swab in infected patient. The disease caused by this novel virus was then named as COVID-19 (Coronavirus Disease 2019). We report a male patient with urticarial lesions, varies on size and shape on the both arms and both legs and diagnosed with COVID-19 confirmed case. He was treated with powdered oral medicine containing combination of lopinavir and ritonavir. He developed urticarial lesions in three hours after administration of the drug. The lesions then dissapeared and resolved after 4 days of treatment using cetirizine. The conclusion of this case is still needed to be proven whether the urticarial lesion is related to COVID-19 or drugs used for COVID-19 therapy.
Page(s): 725-730
DOI: DOI not available
Published: Journal: Journal of Pakistan Association of Dermatologists, Volume: 31, Issue: 4, Year: 2021
Keywords:
COVID19 , infectious disease , urticarial drug eruption , lopinavir , ritonavir
References:
References are not available for this document.
Citations
Citations are not available for this document.
0

Citations

0

Downloads

85

Views